Magellan Health (MGLN) Releases FY18 Earnings Guidance
Magellan Health (NASDAQ:MGLN) issued an update on its FY18 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of $5.68-6.47 for the period, compared to the Thomson Reuters consensus estimate of $5.79. The company issued revenue guidance of $7.5-7.8 billion or $7.0-7.3 billion ex acquisition, compared to the consensus revenue estimate of $7.13 billion.
A number of analysts recently issued reports on the company. BidaskClub raised Magellan Health from a sell rating to a hold rating in a research note on Tuesday, August 8th. KeyCorp reissued a buy rating and set a $89.00 target price on shares of Magellan Health in a research note on Friday, September 22nd. Jefferies Group reissued a buy rating and set a $94.00 target price on shares of Magellan Health in a research note on Friday, October 13th. Zacks Investment Research cut Magellan Health from a buy rating to a hold rating in a research note on Wednesday, October 4th. Finally, ValuEngine raised Magellan Health from a hold rating to a buy rating in a research note on Friday, September 1st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $86.50.
Magellan Health (NASDAQ MGLN) traded down $0.15 during trading hours on Friday, reaching $84.50. The company’s stock had a trading volume of 197,900 shares, compared to its average volume of 139,917. Magellan Health has a 52-week low of $64.05 and a 52-week high of $92.00. The company has a current ratio of 2.28, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62. The firm has a market cap of $2,130.00, a P/E ratio of 19.01, a P/E/G ratio of 1.08 and a beta of 0.55.
In other Magellan Health news, SVP Jeffrey N. West sold 25,316 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $85.85, for a total transaction of $2,173,378.60. Following the completion of the transaction, the senior vice president now owns 29,243 shares of the company’s stock, valued at approximately $2,510,511.55. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Mostafa Kamal sold 1,154 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $92.00, for a total value of $106,168.00. Following the completion of the sale, the chief executive officer now directly owns 1,154 shares of the company’s stock, valued at approximately $106,168. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 245,059 shares of company stock valued at $20,965,135. Insiders own 5.00% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Magellan Health (MGLN) Releases FY18 Earnings Guidance” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/magellan-health-mgln-releases-fy18-earnings-guidance.html.
Magellan Health Company Profile
Magellan Health, Inc is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC).
Receive News & Ratings for Magellan Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.